The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.

doi:10.1016/S2352-3018(25)00164-X

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.

The lancet. HIV - 1 Sept 2025

Hyle Emily P, Bekker Linda-Gail, McCluskey Suzanne M, Chen Wanyi, Sax Paul E, Moosa Mahomed-Yunus, Machoko Munashe, Bangs Audrey, Steegen Kim, Siedner Mark J, van de Vijver David A M C, Resch Stephen C, Neilan Anne M, Phillips Andrew, Walensky Rochelle P, Lessells Richard J, Weinstein Milton C, Dugdale Caitlin M, Wood Robin, Freedberg Kenneth A

Abstract excerpt

BACKGROUND: Persistent virological non-suppression among people with HIV receiving tenofovir-lamivudine-dolutegravir (TLD) can result from poor adherence with or without resistance; however, genotypic resistance testing (GRT) is not recommended routinely in South Africa. We examined the clinical and economic effect of GRT for all South African adults diagnosed with persistent virological non-suppression on TLD....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to South Africa

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 40782815
DOI: 10.1016/S2352-3018(25)00164-X
PMCID: PMC12403227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling study.PMID 40782815Read ↗

Predicting emergent Dolutegravir resistance in South Africa: A modelling studySemantic proximity Read ↗

Opportunities for cost reduction of current first-line WHO-recommended oral antiretroviral therapy: replacing tenofovir disoproxil fumarate with tenofovir alafenamideSemantic proximity Read ↗

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income SettingsSemantic proximity Read ↗

The dolutegravir failure cohort: a multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocolSemantic proximity Read ↗

The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.Semantic proximity Read ↗

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling studySemantic proximity Read ↗

Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan womenSemantic proximity Read ↗

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.Semantic proximity Read ↗

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.Semantic proximity Read ↗

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort studySemantic proximity Read ↗

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.Semantic proximity Read ↗

An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.